Alpha Cognition - ACOGF STOCK NEWS

Alpha Cognition Inc. has successfully closed the first tranche of its private placement, issuing 16,795,221 units at $0.255 per unit, totaling $4,282,781 in gross proceeds. Each unit includes one common share and one warrant, priced at $0.39 for five years. A second tranche is anticipated to close by the end of February 2023, aiming to raise an additional $1.65 million. Proceeds will support clinical development and the filing of a New Drug Application for ALPHA-1062, targeting neurodegenerative disorders. All securities will be subject to a four-month hold period under Canadian laws.

Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced a private placement financing aiming for gross proceeds of up to C$6.8 million (US$5.0 million). This private placement will close around February 15, 2023. The offering includes 26,666,667 units priced at C$0.255 each, with each unit comprising a common share and a warrant for additional shares at $0.39 for five years. Proceeds will support clinical development programs, including a New Drug Application for ALPHA-1062, and general corporate purposes.

Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced the cancellation of 4,655,000 incentive stock options priced between $0.64 CAD and $1.05 CAD. The Board has approved a new grant of 4,655,000 options to directors, officers, employees, and consultants at $0.28 per share, vesting over 8, 18, or 24 months. This strategic move aims to retain talent by aligning compensation with current market pricing. The new options are subject to stock exchange and shareholder approval at the upcoming annual general meeting. Alpha Cognition focuses on innovative therapies for neurodegenerative diseases like Alzheimer's and ALS.

Alpha Cognition Inc. (ACOGF) announced the resignation of Chief Medical Officer, Cedric O’Gorman, who is leaving to pursue other opportunities. The company is actively seeking a replacement while maintaining strong consultant relationships for its upcoming NDA filing for ALPHA-1062, targeting Alzheimer’s Disease. CEO Michael McFadden praised Dr. O’Gorman’s contributions, particularly in achieving positive results for ALPHA-1062. The NDA filing is expected in 2023, indicating a significant step forward for the company in addressing neurodegenerative disorders.

Alpha Cognition (ACOGF) has reported its financial results for Q3 2022, emphasizing preparations for filing a New Drug Application (NDA) for ALPHA-1062, a potential oral therapy for mild to moderate Alzheimer's disease. The company withdrew a previously announced public offering, citing unfavorable market conditions. R&D expenses rose to $1.6 million in Q3, while G&A expenses increased to $0.9 million. The net loss was $2.8 million, a decrease from $4.3 million in Q3 2021. As of September 30, 2022, cash reserves stood at $3.7 million with 61,023,450 shares outstanding.

Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF), a biopharmaceutical company focusing on neurodegenerative disorders, reported its Q2 2022 financial results. Highlights include positive topline data from the ALPHA-1062 pivotal trial, which supports an NDA filing scheduled for Q2 2023. The RESOLVE trial, assessing ALPHA-1062's tolerability in Alzheimer's patients, is set to initiate soon. The company is actively seeking funding and implementing cost-cutting measures to extend its cash runway, with $6.0 million available as of June 30, 2022, and a net loss of $3.4 million for the quarter.

Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced successful results from a bioequivalence study of ALPHA-1062, a delayed release oral tablet for treating mild to moderate Alzheimer’s Disease (AD). The study confirmed ALPHA-1062's equivalency to galantamine hydrobromide formulations, with significant pharmacokinetic results. The data strengthens the forthcoming NDA application, planned for Q2 2023. The Chief Medical Officer highlighted the potential of ALPHA-1062 to limit gastrointestinal side effects, aiming to improve treatment for AD patients.

Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) announced positive results from its pivotal bioequivalence study of ALPHA-1062, a delayed release oral tablet for treating mild to moderate Alzheimer's Disease. The study showed pharmacokinetic equivalence to the reference drug galantamine hydrobromide, with no adverse events reported. The company aims to file a New Drug Application (NDA) in Q2 2023. ALPHA-1062 offers a potentially effective treatment option by minimizing gastrointestinal side effects common with current therapies.

Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) has announced that the European Patent Office confirmed the patentability of EP3009143, related to treating neurodegenerative diseases, following an opposition proceeding. The patent covers a composition that increases progranulin expression, which is linked to motor neuron disease. This complements another patent for treating Alzheimer's and Parkinson's. Additionally, the company has received Orphan Drug Designation for ALPHA-0602, aimed at treating ALS, granting seven years of market exclusivity upon approval.